A Open, Randomized, Single-dose, Comparative Bioequivalency and Safety Study of Human Recombinant Anti-tumor Necrosis Factor Alpha Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Innovent Biologics
- 01 Jun 2018 Status changed from not yet recruiting to completed.
- 30 Sep 2016 New trial record